Literature DB >> 21300968

Ultra-high-field imaging distinguishes MS lesions from asymptomatic white matter lesions.

E C Tallantyre1, J E Dixon, I Donaldson, T Owens, P S Morgan, P G Morris, N Evangelou.   

Abstract

OBJECTIVES: To investigate whether multiple sclerosis (MS) and non-MS white matter brain lesions can be distinguished by their appearance on 7 T T2*-weighted MRI.
METHODS: This was an observational study of 28 patients with MS and 17 patients with cerebral white matter lesions who did not have MS. Subjects were imaged using 7 T T2*-weighted imaging. White matter lesions were identified and analyzed for volume, location, and perivenous appearance.
RESULTS: Out of 901 lesions identified in patients with MS, 80% were perivenous. In comparison, 19% of 428 lesions identified in patients without MS had a perivenous appearance. Seven-Tesla T2*-weighted MRI reliably distinguished all patients with clinically definite MS (>40% lesions appeared perivenous) from those without clinical MS (<40% lesions appeared perivenous). Perivenous lesion appearance was more predictive of MS (odds ratio [OR] 14, p < 0.001) than subcortical or periventricular lesion location (OR 4.5, p < 0.001, and OR 2.4, p = 0.009). Perivenous lesion appearance was observed with a similar frequency in patients with clinically isolated syndrome of demyelination and in early (gadolinium-enhancing) MS lesions.
CONCLUSION: Perivenous lesion location on 7 T T2*-weighted imaging is predictive of the presence of demyelination. Optimization of this imaging technique at lower magnetic resonance field strengths would offer benefit for the diagnosis of MS.

Entities:  

Mesh:

Year:  2011        PMID: 21300968      PMCID: PMC3053180          DOI: 10.1212/WNL.0b013e31820b7630

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  13 in total

1.  Histopathology of multiple sclerosis lesions detected by magnetic resonance imaging in unfixed postmortem central nervous system tissue.

Authors:  J Newcombe; C P Hawkins; C L Henderson; H A Patel; M N Woodroofe; G M Hayes; M L Cuzner; D MacManus; E P du Boulay; W I McDonald
Journal:  Brain       Date:  1991-04       Impact factor: 13.501

2.  Demonstrating the perivascular distribution of MS lesions in vivo with 7-Tesla MRI.

Authors:  E C Tallantyre; M J Brookes; J E Dixon; P S Morgan; N Evangelou; P G Morris
Journal:  Neurology       Date:  2008-05-27       Impact factor: 9.910

3.  Criteria for an increased specificity of MRI interpretation in elderly subjects with suspected multiple sclerosis.

Authors:  F Fazekas; H Offenbacher; S Fuchs; R Schmidt; K Niederkorn; S Horner; H Lechner
Journal:  Neurology       Date:  1988-12       Impact factor: 9.910

4.  Pathologic correlates of incidental MRI white matter signal hyperintensities.

Authors:  F Fazekas; R Kleinert; H Offenbacher; R Schmidt; G Kleinert; F Payer; H Radner; H Lechner
Journal:  Neurology       Date:  1993-09       Impact factor: 9.910

5.  Assessment of MRI criteria for a diagnosis of MS.

Authors:  H Offenbacher; F Fazekas; R Schmidt; W Freidl; E Flooh; F Payer; H Lechner
Journal:  Neurology       Date:  1993-05       Impact factor: 9.910

6.  Presence of a central vein within white matter lesions on susceptibility weighted imaging: a specific finding for multiple sclerosis?

Authors:  Nina Lummel; Tobias Boeckh-Behrens; Veronika Schoepf; Michael Burke; Hartmut Brückmann; Jennifer Linn
Journal:  Neuroradiology       Date:  2010-06-29       Impact factor: 2.804

7.  Stereotaxic display of brain lesions.

Authors:  Chris Rorden; Matthew Brett
Journal:  Behav Neurol       Date:  2000       Impact factor: 3.342

8.  Silent lacunar infarction on magnetic resonance imaging (MRI): risk factors.

Authors:  S Shintani; T Shiigai; T Arinami
Journal:  J Neurol Sci       Date:  1998-09-18       Impact factor: 3.181

Review 9.  Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria".

Authors:  Chris H Polman; Stephen C Reingold; Gilles Edan; Massimo Filippi; Hans-Peter Hartung; Ludwig Kappos; Fred D Lublin; Luanne M Metz; Henry F McFarland; Paul W O'Connor; Magnhild Sandberg-Wollheim; Alan J Thompson; Brian G Weinshenker; Jerry S Wolinsky
Journal:  Ann Neurol       Date:  2005-12       Impact factor: 10.422

10.  Alemtuzumab vs. interferon beta-1a in early multiple sclerosis.

Authors:  Alasdair J Coles; D Alastair S Compston; Krzysztof W Selmaj; Stephen L Lake; Susan Moran; David H Margolin; Kim Norris; P K Tandon
Journal:  N Engl J Med       Date:  2008-10-23       Impact factor: 91.245

View more
  73 in total

Review 1.  Nonconventional MRI and microstructural cerebral changes in multiple sclerosis.

Authors:  Christian Enzinger; Frederik Barkhof; Olga Ciccarelli; Massimo Filippi; Ludwig Kappos; Maria A Rocca; Stefan Ropele; Àlex Rovira; Torben Schneider; Nicola de Stefano; Hugo Vrenken; Claudia Wheeler-Kingshott; Jens Wuerfel; Franz Fazekas
Journal:  Nat Rev Neurol       Date:  2015-11-03       Impact factor: 42.937

2.  Ultra-high-field (7.0 Tesla and above) MRI is now necessary to make the next step forward in understanding MS pathophysiology - YES.

Authors:  Francesca Bagnato; John C Gore
Journal:  Mult Scler       Date:  2016-12-16       Impact factor: 6.312

3.  Comparison of multiecho postprocessing schemes for SWI with use of linear and nonlinear mask functions.

Authors:  M P Quinn; J S Gati; L M Klassen; A W Lin; J R Bird; S E Leung; R S Menon
Journal:  AJNR Am J Neuroradiol       Date:  2013-06-06       Impact factor: 3.825

Review 4.  Current and new directions in MRI in multiple sclerosis.

Authors:  Eric C Klawiter
Journal:  Continuum (Minneap Minn)       Date:  2013-08

5.  Automated Integration of Multimodal MRI for the Probabilistic Detection of the Central Vein Sign in White Matter Lesions.

Authors:  J D Dworkin; P Sati; A Solomon; D L Pham; R Watts; M L Martin; D Ontaneda; M K Schindler; D S Reich; R T Shinohara
Journal:  AJNR Am J Neuroradiol       Date:  2018-09-13       Impact factor: 3.825

6.  Use of Magnetic Resonance Imaging as Well as Clinical Disease Activity in the Clinical Classification of Multiple Sclerosis and Assessment of Its Course: A Report from an International CMSC Consensus Conference, March 5-7, 2010.

Authors:  Stuart D Cook; Suhayl Dhib-Jalbut; Peter Dowling; Luca Durelli; Corey Ford; Gavin Giovannoni; June Halper; Colleen Harris; Joseph Herbert; David Li; John A Lincoln; Robert Lisak; Fred D Lublin; Claudia F Lucchinetti; Wayne Moore; Robert T Naismith; Carlos Oehninger; Jack Simon; Maria Pia Sormani
Journal:  Int J MS Care       Date:  2012

Review 7.  Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis-clinical implementation in the diagnostic process.

Authors:  Àlex Rovira; Mike P Wattjes; Mar Tintoré; Carmen Tur; Tarek A Yousry; Maria P Sormani; Nicola De Stefano; Massimo Filippi; Cristina Auger; Maria A Rocca; Frederik Barkhof; Franz Fazekas; Ludwig Kappos; Chris Polman; David Miller; Xavier Montalban
Journal:  Nat Rev Neurol       Date:  2015-07-07       Impact factor: 42.937

8.  Morphological features of MS lesions on FLAIR* at 7 T and their relation to patient characteristics.

Authors:  Iris D Kilsdonk; Alexandra Lopez-Soriano; Joost P A Kuijer; Wolter L de Graaf; Jonas A Castelijns; Chris H Polman; Peter R Luijten; Jeroen J J G Geurts; Frederik Barkhof; Mike P Wattjes
Journal:  J Neurol       Date:  2014-04-29       Impact factor: 4.849

Review 9.  Imaging as an Outcome Measure in Multiple Sclerosis.

Authors:  Daniel Ontaneda; Robert J Fox
Journal:  Neurotherapeutics       Date:  2017-01       Impact factor: 7.620

Review 10.  [Ultrahigh field MRI in context of neurological diseases].

Authors:  J Kuchling; T Sinnecker; I Bozin; J Dörr; V I Madai; J Sobesky; T Niendorf; F Paul; J Wuerfel
Journal:  Nervenarzt       Date:  2014-04       Impact factor: 1.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.